🔎 Trials Near Me

Utama › Leukemia › New York

Kajian klinikal Leukemia di New York

26 kajian untuk Leukemia sedang mencari peserta di lokasi di New York.

Bandar di New York

Teks kajian rasmi (Bahasa Inggeris)

Pivotal Open-label Phase 3 Clinical Study of QTX-2101 in Adult Patients With Acute Promyelocytic Leukemia

  • Quetzal Site 4, Buffalo
  • Quetzal Site 2, The Bronx
Mengambil pesertaFasa 3
Umur 18 hingga 71 · Semua jantina · Dikemas kini 23 Sep 2026 · NCT07504458

A Study of Revumenib in R/R Leukemias Including Those With an MLL/KMT2A Gene Rearrangement or NPM1 Mutation

  • Montefiore Medical Center, New York
Mengambil pesertaFasa 1/2
30 Days · Semua jantina · Dikemas kini 16 Sep 2026 · NCT04065399

Evaluation of Two Dose Levels of Quizartinib as Maintenance in FLT3-ITD (+) Acute Myeloid Leukemia Patients in Complete Remission

  • Weill Cornell, New York
  • Clinical Research Allicance, Westbury
Mengambil pesertaFasa 2
Umur 18 ke atas · Semua jantina · Dikemas kini 16 Sep 2026 · NCT06824168

A Phase II Study of the Menin Inhibitor Revumenib in Leukemia Associated With Upregulation of HOX Genes

  • Memorial Sloan Kettering Cancer Center, New York
Mengambil pesertaFasa 2
Umur 12 ke atas · Semua jantina · Dikemas kini 11 Sep 2026 · NCT06229912

Surovatamig as Consolidation Therapy in Participants With Chronic Lymphocytic Leukaemia or Small Lymphocytic Lymphoma With Unmutated Immunoglobulin Heavy Chain Variable (IGHV)

  • Research Site, Rochester
Mengambil pesertaFasa 3
Umur 18 hingga 18 · Semua jantina · Dikemas kini 8 Sep 2026 · NCT07509151

Study to Determine the Efficacy and Safety of Asciminib in Pediatric Patients With Ph+ CML-CP

  • Columbia University Medical Center New York Presbyterian, New York
Mengambil pesertaFasa 2
Umur 1 hingga 18 · Semua jantina · Dikemas kini 2 Sep 2026 · NCT07354074

Studies to Assess Ziftomenib in Combination With Ven+Aza or 7+3 in Patients With Untreated NPM1-m or KMT2A-r AML

  • State University of New York at Buffalo, Buffalo
  • Icahn School of Medicine at Mount Sinai, New York
  • Columbia University, New York
  • dan 1 lagi
Mengambil pesertaFasa 3
Umur 18 ke atas · Semua jantina · Dikemas kini 20 Ogo 2026 · NCT07007312

Safety and Tolerability of Ziftomenib Combinations in Patients With Relapsed/Refractory Acute Myeloid Leukemia

  • Roswell Park Comprehensive Cancer Center, Buffalo
  • Northwell Health, LLC PRIME, Lake Success
  • Memorial Sloan Kettering Cancer Center, New York
  • dan 3 lagi
Mengambil pesertaFasa 1
Umur 18 ke atas · Semua jantina · Dikemas kini 20 Ogo 2026 · NCT06001788

AZD0486 as Monotherapy in B-cell Acute Lymphoblastic Leukaemia

  • Research Site, New York
Mengambil pesertaFasa 1/2
Umur 12 ke atas · Semua jantina · Dikemas kini 19 Ogo 2026 · NCT06137118

Gene Therapy for CD19-Positive Hematologic Malignancies (SENTRY-CD19)

  • New York Medical College, Valhalla
Mengambil pesertaFasa 1/2
Umur 13 hingga 90 · Semua jantina · Dikemas kini 6 Ogo 2026 · NCT06533579

Genomically Profiling, Collecting, Archiving and Distributing Hematologic Malignancy Specimens

  • Albany Medical Center, Albany
Mengambil pesertaKajian pemerhatian
Sehingga umur 30 · Semua jantina · Dikemas kini 16 Jul 2026 · NCT04968834

Trial of Orca-T Following Reduced Intensity or Nonmyeloablative Conditioning in Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome

  • Weill Cornell Medicine - New York Presbyterian Hospital, New York
Mengambil pesertaFasa 2
Umur 18 ke atas · Semua jantina · Dikemas kini 7 Jul 2026 · NCT07216443

Hairy Cell Leukemia Patient Data Registry

  • University of Rochester /Wilmot Cancer Institute, Rochester
Mengambil pesertaKajian pemerhatian
Umur 18 ke atas · Semua jantina · Dikemas kini 2 Jul 2026 · NCT02560883

Integrated Cancer Repository for Cancer Research

  • C.R. Wood Cancer Center, Glens Falls Hospital, Glens Falls
  • Faxton St. Luke's Healthcare, Mohawk Valley, Utica
Mengambil pesertaKajian pemerhatianSukarelawan sihat dialu-alukan
Umur 19 hingga 110 · Semua jantina · Dikemas kini 29 Jun 2026 · NCT02012699

CD4CAR for CD4+ Leukemia and Lymphoma

  • Albert Einstein Health Network, New York
Mengambil pesertaFasa 1
Umur 12 ke atas · Semua jantina · Dikemas kini 24 Jun 2026 · NCT03829540

A Study of Revumenib and Mezigdomide in People With Leukemia

  • Memorial Sloan Kettering Suffolk-Commack (All Protocol Activities), Commack
  • Memorial Sloan Kettering Westchester (Limited Protocol Activities), Harrison
  • Memorial Sloan Kettering Cancer Center (All Protocol Activities), New York
  • dan 1 lagi
Mengambil pesertaFasa 1/2
Umur 12 ke atas · Semua jantina · Dikemas kini 22 Jun 2026 · NCT07356154

A Study of DR-01 in Subjects With Large Granular Lymphocytic Leukemia or Cytotoxic Lymphomas

  • Dren Investigational Site 1, New York
  • Dren Investigational Site 2, New York
Mengambil pesertaFasa 1/2
Umur 18 ke atas · Semua jantina · Dikemas kini 17 Jun 2026 · NCT05475925

A Music Therapy Study for Blood Cancer Survivors With Cognitive Difficulties

  • Memorial Sloan Kettering Cancer Center Suffolk - Commack (All protocol activities), Commack
  • Memorial Sloan Kettering Westchester (All protocol activities), Harrison
  • Memorial Sloan Kettering Cancer Center (All protocol activities), New York
  • dan 1 lagi
Mengambil pesertaSukarelawan sihat dialu-alukan
Umur 18 ke atas · Semua jantina · Dikemas kini 26 Mei 2026 · NCT07052916

Effects of Dexrazoxane Hydrochloride on Biomarkers Associated With Cardiomyopathy and Heart Failure After Cancer Treatment

  • The Steven and Alexandra Cohen Children's Medical Center of New York, New Hyde Park
  • University of Rochester, Rochester
  • Stony Brook University Medical Center, Stony Brook
  • dan 1 lagi
Mengambil pesertaKajian pemerhatian
Semua umur · Semua jantina · Dikemas kini 18 Mei 2026 · NCT01790152

Cord Blood Transplantation in Children and Young Adults With Blood Cancer

  • Memorial Sloan Kettering Cancer Center (All Protocol Activities), New York
Mengambil pesertaFasa 2
Sehingga umur 26 · Semua jantina · Dikemas kini 14 Mei 2026 · NCT07566377

A Multi-phase Study of ASTX030 (Azacitidine and Cedazuridine) in Myeloid Neoplasm Alone or in Combination With Venetoclax in AML (AZTOUND Study)

  • Roswell Park Comprehensive Cancer Center, Buffalo
  • New York University Langone Hospital - Long Island, Mineola
  • Perlmutter Cancer Center - 34th Street, New York
  • dan 2 lagi
Mengambil pesertaFasa 2/3
Umur 18 ke atas · Semua jantina · Dikemas kini 30 Apr 2026 · NCT04256317

A Study to Investigate the Safety and Tolerability of Ziftomenib in Combination With Venetoclax/Azacitidine, Venetoclax, 7+3, or 7+3+Quizartinib in Patients With AML

  • Roswell Park Comprehensive Cancer Center, Buffalo
  • New York - Presbyterian / Weill Cornell Medicine, New York
  • Mount Sinai - Ruttenberg Treatment Center, New York
  • dan 2 lagi
Mengambil pesertaFasa 1
Umur 18 ke atas · Semua jantina · Dikemas kini 13 Mac 2026 · NCT05735184

Ascertainment of Families for Genetic Studies of Familial Lymphoproliferative Disorders

  • Memorial Sloan Kettering Commack, Commack
  • Memorial Sloan Kettering Westchester, Harrison
  • Memorial Sloan Kettering Cancer Center, New York
  • dan 1 lagi
Mengambil pesertaKajian pemerhatianSukarelawan sihat dialu-alukan
Semua umur · Semua jantina · Dikemas kini 23 Jan 2026 · NCT00582621

SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry

  • Massive Bio SYNERGY-AI site, Buffalo
  • Massive Bio SYNERGY-AI site, Hempstead
  • Massive Bio SYNERGY-AI site, Manhasset
  • dan 2 lagi
Mengambil pesertaKajian pemerhatian
Semua umur · Semua jantina · Dikemas kini 28 Okt 2025 · NCT03452774

A Study of BH-30236 in Relapsed/ Refractory Acute Myelogenous Leukemia and Higher Risk Myelodysplastic Syndrome

  • Roswell Park Cancer Institute, Buffalo
  • Memorial Sloan Kettering Cancer Center, New York
Mengambil pesertaFasa 1
Umur 18 ke atas · Semua jantina · Dikemas kini 24 Sep 2025 · NCT06501196

Daripada ClinicalTrials.gov, data diperoleh pada 4 Okt 2026. Setiap kajian menetapkan kriteria kelayakannya sendiri; pasukan kajian menentukan siapa yang layak menyertai.